Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1

Background Neoangiogenesis is essential for tumor growth. The present study aimed to test the hypothesis that vector‐mediated expression of sflt1 at high levels would result in the blockade of vascular endothelial growth factor (VEGF) function and therefore the inhibition of tumor growth. Methods To...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of gene medicine 2008-10, Vol.10 (10), p.1083-1091
Hauptverfasser: Ganesh Sivanandam, Vijayshankar, Stephen, Sam Laurel, Hernandez-Alcoceba, Ruben, Alzuguren, Pilar, Zabala, Maider, van Rooijen, Nico, Qian, Cheng, Berger, Irina, Gross, Marie-Luise, Prieto, Jesus, Kochanek, Stefan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1091
container_issue 10
container_start_page 1083
container_title The journal of gene medicine
container_volume 10
creator Ganesh Sivanandam, Vijayshankar
Stephen, Sam Laurel
Hernandez-Alcoceba, Ruben
Alzuguren, Pilar
Zabala, Maider
van Rooijen, Nico
Qian, Cheng
Berger, Irina
Gross, Marie-Luise
Prieto, Jesus
Kochanek, Stefan
description Background Neoangiogenesis is essential for tumor growth. The present study aimed to test the hypothesis that vector‐mediated expression of sflt1 at high levels would result in the blockade of vascular endothelial growth factor (VEGF) function and therefore the inhibition of tumor growth. Methods To sequester VEGF, we tested, in a subcutaneous LLC tumor model, ‘gutless’ high‐capacity adenovirus vectors expressing the soluble VEGF receptor 1 (sflt1) in a liver‐specific manner, either in a constitutive or in a RU486 induced manner. Results High serum levels of sflt1 were observed upon in vivo injection of both vectors. Despite the differences in expression kinetics, both modes of sflt1 expression resulted in significant though transient suppression of tumor growth. Unexpectedly, constitutive but not intermittent sflt1 expression resulted in ascites and death of all animals. Morphological analyses by light and electron microscopy indicated that the animals had died from a nephropathy, which apparently was due to the blockade of VEGF function. Conclusions Although confirming earlier results of toxic effects of prolonged VEGF sequestration, the present study suggests that therapeutic anti‐tumor effects can be achieved without side‐effects with intermittent VEGF blockade or the use of drugs with short half‐lives, as shown by the use of an inducible gene expression system. Copyright © 2008 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/jgm.1244
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1757699779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3924187751</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3854-21b183b7317ee1d537c7cb061bd51a7ed875173ce495ccfe969817eec26ac5913</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi1ERUtB4gmQJTZsUuwkjuMlmsJwGWBTVHaW45zMeEji1Je28z59UBxNRFeVLPmXzufvSP4RekPJBSUk_7DfDhc0L8tn6IyynGZ5zsrnKRMhslLUf07RS-_3hFBe1-IFOqU1z0lZkDP0sIGwU70JB2xGrOYTTKbGrbFbGI3GIQ7W4ZQBhx04NR3wYFvocZzsiLUdfTAhBnMLuIkBjzYkURu1aXrAcD858N4k0nbze-xtH-fJrfI69sphGFubBr1RPd46exd2uFM6pJ0ONExzoK_QSad6D6-X-xz9_vzpavUl2_xaf1193GS6qFmZ5bShddHwgnIA2rKCa64bUtGmZVRxaGvOKC80lIJp3YGoRD2jOq-UZoIW5-jd0Ts5exPBB7m30Y1ppaSc8UoIzkWi3h8p7az3Djo5OTMod5CUyLkOmeqQcx0JfbsIYzNA-wgu_5-A7AjcmR4OT4rkt_WPRbjwxge4_88r91dWvOBMXv9cS351ef09Z5dyVfwDZp2mqQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1757699779</pqid></control><display><type>article</type><title>Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Ganesh Sivanandam, Vijayshankar ; Stephen, Sam Laurel ; Hernandez-Alcoceba, Ruben ; Alzuguren, Pilar ; Zabala, Maider ; van Rooijen, Nico ; Qian, Cheng ; Berger, Irina ; Gross, Marie-Luise ; Prieto, Jesus ; Kochanek, Stefan</creator><creatorcontrib>Ganesh Sivanandam, Vijayshankar ; Stephen, Sam Laurel ; Hernandez-Alcoceba, Ruben ; Alzuguren, Pilar ; Zabala, Maider ; van Rooijen, Nico ; Qian, Cheng ; Berger, Irina ; Gross, Marie-Luise ; Prieto, Jesus ; Kochanek, Stefan</creatorcontrib><description>Background Neoangiogenesis is essential for tumor growth. The present study aimed to test the hypothesis that vector‐mediated expression of sflt1 at high levels would result in the blockade of vascular endothelial growth factor (VEGF) function and therefore the inhibition of tumor growth. Methods To sequester VEGF, we tested, in a subcutaneous LLC tumor model, ‘gutless’ high‐capacity adenovirus vectors expressing the soluble VEGF receptor 1 (sflt1) in a liver‐specific manner, either in a constitutive or in a RU486 induced manner. Results High serum levels of sflt1 were observed upon in vivo injection of both vectors. Despite the differences in expression kinetics, both modes of sflt1 expression resulted in significant though transient suppression of tumor growth. Unexpectedly, constitutive but not intermittent sflt1 expression resulted in ascites and death of all animals. Morphological analyses by light and electron microscopy indicated that the animals had died from a nephropathy, which apparently was due to the blockade of VEGF function. Conclusions Although confirming earlier results of toxic effects of prolonged VEGF sequestration, the present study suggests that therapeutic anti‐tumor effects can be achieved without side‐effects with intermittent VEGF blockade or the use of drugs with short half‐lives, as shown by the use of an inducible gene expression system. Copyright © 2008 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 1099-498X</identifier><identifier>EISSN: 1521-2254</identifier><identifier>DOI: 10.1002/jgm.1244</identifier><identifier>PMID: 18720430</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Adenoviridae - genetics ; Adenoviridae - metabolism ; adenovirus vector ; Angiogenesis Inhibitors - genetics ; Angiogenesis Inhibitors - metabolism ; Animals ; Cell Differentiation ; Cell Line, Tumor ; Cell Proliferation ; Gene Expression ; Gene therapy ; Genetic Therapy ; Genetic Vectors - administration &amp; dosage ; HeLa Cells ; Humans ; Liver - metabolism ; Mice ; Mice, Inbred C57BL ; Neoplasms, Experimental - therapy ; Neovascularization, Pathologic ; sflt1 ; toxicity ; Transfection ; tumor ; Tumor Cells, Cultured ; Vascular Endothelial Growth Factor Receptor-1 - genetics ; Vascular Endothelial Growth Factor Receptor-1 - metabolism ; VEGF</subject><ispartof>The journal of gene medicine, 2008-10, Vol.10 (10), p.1083-1091</ispartof><rights>Copyright © 2008 John Wiley &amp; Sons, Ltd.</rights><rights>Copyright (c) 2008 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3854-21b183b7317ee1d537c7cb061bd51a7ed875173ce495ccfe969817eec26ac5913</citedby><cites>FETCH-LOGICAL-c3854-21b183b7317ee1d537c7cb061bd51a7ed875173ce495ccfe969817eec26ac5913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjgm.1244$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjgm.1244$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18720430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ganesh Sivanandam, Vijayshankar</creatorcontrib><creatorcontrib>Stephen, Sam Laurel</creatorcontrib><creatorcontrib>Hernandez-Alcoceba, Ruben</creatorcontrib><creatorcontrib>Alzuguren, Pilar</creatorcontrib><creatorcontrib>Zabala, Maider</creatorcontrib><creatorcontrib>van Rooijen, Nico</creatorcontrib><creatorcontrib>Qian, Cheng</creatorcontrib><creatorcontrib>Berger, Irina</creatorcontrib><creatorcontrib>Gross, Marie-Luise</creatorcontrib><creatorcontrib>Prieto, Jesus</creatorcontrib><creatorcontrib>Kochanek, Stefan</creatorcontrib><title>Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1</title><title>The journal of gene medicine</title><addtitle>J. Gene Med</addtitle><description>Background Neoangiogenesis is essential for tumor growth. The present study aimed to test the hypothesis that vector‐mediated expression of sflt1 at high levels would result in the blockade of vascular endothelial growth factor (VEGF) function and therefore the inhibition of tumor growth. Methods To sequester VEGF, we tested, in a subcutaneous LLC tumor model, ‘gutless’ high‐capacity adenovirus vectors expressing the soluble VEGF receptor 1 (sflt1) in a liver‐specific manner, either in a constitutive or in a RU486 induced manner. Results High serum levels of sflt1 were observed upon in vivo injection of both vectors. Despite the differences in expression kinetics, both modes of sflt1 expression resulted in significant though transient suppression of tumor growth. Unexpectedly, constitutive but not intermittent sflt1 expression resulted in ascites and death of all animals. Morphological analyses by light and electron microscopy indicated that the animals had died from a nephropathy, which apparently was due to the blockade of VEGF function. Conclusions Although confirming earlier results of toxic effects of prolonged VEGF sequestration, the present study suggests that therapeutic anti‐tumor effects can be achieved without side‐effects with intermittent VEGF blockade or the use of drugs with short half‐lives, as shown by the use of an inducible gene expression system. Copyright © 2008 John Wiley &amp; Sons, Ltd.</description><subject>Adenoviridae - genetics</subject><subject>Adenoviridae - metabolism</subject><subject>adenovirus vector</subject><subject>Angiogenesis Inhibitors - genetics</subject><subject>Angiogenesis Inhibitors - metabolism</subject><subject>Animals</subject><subject>Cell Differentiation</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Gene Expression</subject><subject>Gene therapy</subject><subject>Genetic Therapy</subject><subject>Genetic Vectors - administration &amp; dosage</subject><subject>HeLa Cells</subject><subject>Humans</subject><subject>Liver - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Neoplasms, Experimental - therapy</subject><subject>Neovascularization, Pathologic</subject><subject>sflt1</subject><subject>toxicity</subject><subject>Transfection</subject><subject>tumor</subject><subject>Tumor Cells, Cultured</subject><subject>Vascular Endothelial Growth Factor Receptor-1 - genetics</subject><subject>Vascular Endothelial Growth Factor Receptor-1 - metabolism</subject><subject>VEGF</subject><issn>1099-498X</issn><issn>1521-2254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1DAUhi1ERUtB4gmQJTZsUuwkjuMlmsJwGWBTVHaW45zMeEji1Je28z59UBxNRFeVLPmXzufvSP4RekPJBSUk_7DfDhc0L8tn6IyynGZ5zsrnKRMhslLUf07RS-_3hFBe1-IFOqU1z0lZkDP0sIGwU70JB2xGrOYTTKbGrbFbGI3GIQ7W4ZQBhx04NR3wYFvocZzsiLUdfTAhBnMLuIkBjzYkURu1aXrAcD858N4k0nbze-xtH-fJrfI69sphGFubBr1RPd46exd2uFM6pJ0ONExzoK_QSad6D6-X-xz9_vzpavUl2_xaf1193GS6qFmZ5bShddHwgnIA2rKCa64bUtGmZVRxaGvOKC80lIJp3YGoRD2jOq-UZoIW5-jd0Ts5exPBB7m30Y1ppaSc8UoIzkWi3h8p7az3Djo5OTMod5CUyLkOmeqQcx0JfbsIYzNA-wgu_5-A7AjcmR4OT4rkt_WPRbjwxge4_88r91dWvOBMXv9cS351ef09Z5dyVfwDZp2mqQ</recordid><startdate>200810</startdate><enddate>200810</enddate><creator>Ganesh Sivanandam, Vijayshankar</creator><creator>Stephen, Sam Laurel</creator><creator>Hernandez-Alcoceba, Ruben</creator><creator>Alzuguren, Pilar</creator><creator>Zabala, Maider</creator><creator>van Rooijen, Nico</creator><creator>Qian, Cheng</creator><creator>Berger, Irina</creator><creator>Gross, Marie-Luise</creator><creator>Prieto, Jesus</creator><creator>Kochanek, Stefan</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley Periodicals Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>200810</creationdate><title>Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1</title><author>Ganesh Sivanandam, Vijayshankar ; Stephen, Sam Laurel ; Hernandez-Alcoceba, Ruben ; Alzuguren, Pilar ; Zabala, Maider ; van Rooijen, Nico ; Qian, Cheng ; Berger, Irina ; Gross, Marie-Luise ; Prieto, Jesus ; Kochanek, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3854-21b183b7317ee1d537c7cb061bd51a7ed875173ce495ccfe969817eec26ac5913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adenoviridae - genetics</topic><topic>Adenoviridae - metabolism</topic><topic>adenovirus vector</topic><topic>Angiogenesis Inhibitors - genetics</topic><topic>Angiogenesis Inhibitors - metabolism</topic><topic>Animals</topic><topic>Cell Differentiation</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Gene Expression</topic><topic>Gene therapy</topic><topic>Genetic Therapy</topic><topic>Genetic Vectors - administration &amp; dosage</topic><topic>HeLa Cells</topic><topic>Humans</topic><topic>Liver - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Neoplasms, Experimental - therapy</topic><topic>Neovascularization, Pathologic</topic><topic>sflt1</topic><topic>toxicity</topic><topic>Transfection</topic><topic>tumor</topic><topic>Tumor Cells, Cultured</topic><topic>Vascular Endothelial Growth Factor Receptor-1 - genetics</topic><topic>Vascular Endothelial Growth Factor Receptor-1 - metabolism</topic><topic>VEGF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ganesh Sivanandam, Vijayshankar</creatorcontrib><creatorcontrib>Stephen, Sam Laurel</creatorcontrib><creatorcontrib>Hernandez-Alcoceba, Ruben</creatorcontrib><creatorcontrib>Alzuguren, Pilar</creatorcontrib><creatorcontrib>Zabala, Maider</creatorcontrib><creatorcontrib>van Rooijen, Nico</creatorcontrib><creatorcontrib>Qian, Cheng</creatorcontrib><creatorcontrib>Berger, Irina</creatorcontrib><creatorcontrib>Gross, Marie-Luise</creatorcontrib><creatorcontrib>Prieto, Jesus</creatorcontrib><creatorcontrib>Kochanek, Stefan</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>The journal of gene medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ganesh Sivanandam, Vijayshankar</au><au>Stephen, Sam Laurel</au><au>Hernandez-Alcoceba, Ruben</au><au>Alzuguren, Pilar</au><au>Zabala, Maider</au><au>van Rooijen, Nico</au><au>Qian, Cheng</au><au>Berger, Irina</au><au>Gross, Marie-Luise</au><au>Prieto, Jesus</au><au>Kochanek, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1</atitle><jtitle>The journal of gene medicine</jtitle><addtitle>J. Gene Med</addtitle><date>2008-10</date><risdate>2008</risdate><volume>10</volume><issue>10</issue><spage>1083</spage><epage>1091</epage><pages>1083-1091</pages><issn>1099-498X</issn><eissn>1521-2254</eissn><abstract>Background Neoangiogenesis is essential for tumor growth. The present study aimed to test the hypothesis that vector‐mediated expression of sflt1 at high levels would result in the blockade of vascular endothelial growth factor (VEGF) function and therefore the inhibition of tumor growth. Methods To sequester VEGF, we tested, in a subcutaneous LLC tumor model, ‘gutless’ high‐capacity adenovirus vectors expressing the soluble VEGF receptor 1 (sflt1) in a liver‐specific manner, either in a constitutive or in a RU486 induced manner. Results High serum levels of sflt1 were observed upon in vivo injection of both vectors. Despite the differences in expression kinetics, both modes of sflt1 expression resulted in significant though transient suppression of tumor growth. Unexpectedly, constitutive but not intermittent sflt1 expression resulted in ascites and death of all animals. Morphological analyses by light and electron microscopy indicated that the animals had died from a nephropathy, which apparently was due to the blockade of VEGF function. Conclusions Although confirming earlier results of toxic effects of prolonged VEGF sequestration, the present study suggests that therapeutic anti‐tumor effects can be achieved without side‐effects with intermittent VEGF blockade or the use of drugs with short half‐lives, as shown by the use of an inducible gene expression system. Copyright © 2008 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>18720430</pmid><doi>10.1002/jgm.1244</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1099-498X
ispartof The journal of gene medicine, 2008-10, Vol.10 (10), p.1083-1091
issn 1099-498X
1521-2254
language eng
recordid cdi_proquest_journals_1757699779
source MEDLINE; Wiley Online Library All Journals
subjects Adenoviridae - genetics
Adenoviridae - metabolism
adenovirus vector
Angiogenesis Inhibitors - genetics
Angiogenesis Inhibitors - metabolism
Animals
Cell Differentiation
Cell Line, Tumor
Cell Proliferation
Gene Expression
Gene therapy
Genetic Therapy
Genetic Vectors - administration & dosage
HeLa Cells
Humans
Liver - metabolism
Mice
Mice, Inbred C57BL
Neoplasms, Experimental - therapy
Neovascularization, Pathologic
sflt1
toxicity
Transfection
tumor
Tumor Cells, Cultured
Vascular Endothelial Growth Factor Receptor-1 - genetics
Vascular Endothelial Growth Factor Receptor-1 - metabolism
VEGF
title Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T17%3A57%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lethality%20in%20an%20anti-angiogenic%20tumor%20gene%20therapy%20model%20upon%20constitutive%20but%20not%20inducible%20expression%20of%20the%20soluble%20vascular%20endothelial%20growth%20factor%20receptor%201&rft.jtitle=The%20journal%20of%20gene%20medicine&rft.au=Ganesh%20Sivanandam,%20Vijayshankar&rft.date=2008-10&rft.volume=10&rft.issue=10&rft.spage=1083&rft.epage=1091&rft.pages=1083-1091&rft.issn=1099-498X&rft.eissn=1521-2254&rft_id=info:doi/10.1002/jgm.1244&rft_dat=%3Cproquest_cross%3E3924187751%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1757699779&rft_id=info:pmid/18720430&rfr_iscdi=true